Myriad Genetics (MYGN) Asset Writedowns and Impairment (2009 - 2026)

Myriad Genetics (MYGN) has 17 years of Asset Writedowns and Impairment data on file, last reported at $5.4 million in Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $5.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $324.8 million (up 486.28% YoY), and the FY2025 annual result was $319.4 million, up 464.31% from the prior year.
• Asset Writedowns and Impairment advanced to $5.4 million in Q1 2026 per MYGN's latest filing, from $2.7 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $316.7 million in Q2 2025 and troughed at $800000.0 in Q3 2024.
• A 4-year average of $44.3 million and a median of $6.2 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 2630.17% in 2025 and fell as far as 93.72% in 2025.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $6.2 million in 2022, then jumped by 593.55% to $43.0 million in 2024, then sank by 93.72% to $2.7 million in 2025, then jumped by 100.0% to $5.4 million in 2026.
• Business Quant data shows MYGN's Asset Writedowns and Impairment at $5.4 million in Q1 2026, $2.7 million in Q4 2025, and $316.7 million in Q2 2025.